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Abstract
Adaptive stress response pathways play a key role in the switch between adaptation and adversity, and are important in drug-
induced liver injury. Previously, we have established an HepG2 fluorescent protein reporter platform to monitor adaptive 
stress response activation following drug treatment. HepG2 cells are often used in high-throughput primary toxicity screening, 
but metabolizing capacity in these cells is low and repeated dose toxicity testing inherently difficult. Here, we applied our 
bacterial artificial chromosome-based GFP reporter cell lines representing Nrf2 activation (Srxn1-GFP and NQO1-GFP), 
unfolded protein response (BiP-GFP and Chop-GFP), and DNA damage response (p21-GFP and Btg2-GFP) as long-term 
differentiated 3D liver-like spheroid cultures. All HepG2 GFP reporter lines differentiated into 3D spheroids similar to 
wild-type HepG2 cells. We systematically optimized the automated imaging and quantification of GFP reporter activity in 
individual spheroids using high-throughput confocal microscopy with a reference set of DILI compounds that activate these 
three stress response pathways at the transcriptional level in primary human hepatocytes. A panel of 33 compounds with 
established DILI liability was further tested in these six 3D GFP reporters in single 48 h treatment or 6 day daily repeated 
treatment. Strongest stress response activation was observed after 6-day repeated treatment, with the BiP and Srxn1-GFP 
reporters being most responsive and identified particular severe-DILI-onset compounds. Compounds that showed no GFP 
reporter activation in two-dimensional (2D) monolayer demonstrated GFP reporter stress response activation in 3D sphe-
roids. Our data indicate that the application of BAC-GFP HepG2 cellular stress reporters in differentiated 3D spheroids is a 
promising strategy for mechanism-based identification of compounds with liability for DILI.
Keywords High-throughput imaging · HepG2 spheroids · Drug-induced liver injury · BAC-reporter cells · Cellular stress 
response · Liver transcription factors
Introduction
Drug-induced liver injury (DILI) is a major problem in 
the clinic, as 50% of all liver failures are caused by drugs 
(Ostapowicz et al. 2002). In 13% of these cases, liver failure 
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is caused by idiosyncratic drug reactions. Idiosyncratic DILI 
occurs only in rare cases, in approximately 0.1–0.01% of 
patients administrating the drug, and has a variable latency 
time, ranging from a few days up to a few years after first 
administration of the drug. These properties make it com-
plicated to predict which drug will eventually cause idi-
osyncratic DILI in the clinic. Therefore, idiosyncratic DILI 
onset is often missed in preclinical toxicity assessment dur-
ing drug development; hence, DILI is the leading cause for 
drug withdrawal from the market (Wilke et al. 2007).
Traditionally, in vitro tools have been used during preclin-
ical toxicity to screen for cell viability in simple end-point 
measurements. However, these assays do not reflect the early 
cell state changes occurring when cells adapt to the insult 
induced by the candidate chemical entity. This is valuable 
information as idiosyncratic DILI only occurs in suscep-
tible individuals and likely also involves initial cell injury 
to hepatocytes. Therefore, over the past decade, transcrip-
tomic approaches have unraveled some of the mechanisms 
of action by which the drugs with DILI liabilities affect the 
cellular homeostasis (Cui and Paules 2010; Jennings et al. 
2013; Jiang et al. 2015). While transcriptomics has allowed 
identification of global cellular changes at the transcrip-
tional level following drug exposure, it has deemed less 
suitable in the evaluation of pharmaceutical safety. Limita-
tions in concentration and time courses have prevented the 
clear identification of benchmark concentrations for point 
of departure of cellular perturbations. Furthermore, while 
mRNA expression levels can be indicative of cellular func-
tion, they do not necessarily represent the changes in the 
cellular protein landscape after drug exposure. In addition, 
not only up- or down-regulation of genes affects the overall 
biological outcome of drug exposure, e.g., as a consequence 
of post-translational modification and changes in cellular 
location determine protein function and, hence, the cell bio-
logically. To overcome some of these limitations, we have 
built a fluorescent-based proteomic platform to screen for 
critical early cell state changes after drug exposure (Wink 
et al. 2016). Using bacterial artificial chromosome recom-
bineering technology (Poser et al. 2008), we tagged indi-
vidual components of three different stress response path-
ways with green fluorescent protein (GFP): oxidative stress, 
unfolded protein response and DNA damage (Wink et al. 
2016). Using high-content live cell confocal microscopy, 
we can quantitatively evaluate the dynamics of the activa-
tion of individual stress response pathway components at the 
individual cell level (Wink et al. 2016, 2018).
Different in vitro liver cell lines are used in toxicity 
screening. Primary human hepatocytes (PHH) are viewed 
the ‘golden standard’ in in vitro liver toxicity screening, as 
they have the best representation of the human liver in terms 
of liver functional properties (Soldatow et al. 2013). Major 
shortcomings of the use of primary human hepatocytes 
are the limited batch size, donor variability, and high costs 
(LeCluyse et al. 2012). The liver carcinoma cell line HepG2 
is an economical, easy to use cell line with unlimited lifes-
pan, which makes it highly suitable for high-throughput 
toxicity screening. We have used the HepG2 cell line to 
establish the BAC-GFP reporter platform. These reporters 
show excellent performance in detecting mode-of-action of 
stress response activation (Wink et al. 2018). A caveat of 
HepG2 cells cultured in a conventional 2D monolayer is the 
high proliferative capacity and a dedifferentiated phenotype 
(LeCluyse et al. 2012). Thus, limited drug metabolism—
capacity or liver properties like bile duct formation and albu-
min expression are present. In addition, 2D cultured HepG2 
are not optimally suited for repeated dose exposures, due to 
the high proliferative capacity.
Previously, we reported an advanced HepG2 3D sphe-
roid model with a highly differentiated liver-like phenotype, 
which is suitable for high-throughput screening (Ramaiah-
gari et al. 2014). By culturing HepG2 cells in a matrigel 
matrix, cells stop proliferating and start differentiating 
with neonatal-hepatocytes-like properties. Within 21 days, 
HepG2 spheroids are formed which start to increase the 
expression of phase I and II metabolizing enzymes and 
phase III transporters. Furthermore, liver-specific func-
tions such as bile duct formation and glycogen storage are 
increased. Given the stability of these HepG2 spheroid cul-
tures, repeated treatment over a prolonged period of time is 
feasible.
The goal of the current study was to evaluate the applica-
tion of the HepG2 stress response reporters in 3D spheroid 
systems in combination with high-throughput microscopy. 
The data demonstrate that the GFP reporter platform can be 
used effectively and efficiently for repeated dose exposure 




All compounds used were obtained from Sigma (Zwi-
jndrecht, The Netherlands), except for: acetaminophen, 
amiodarone, bosentan, clozapine, diclofenac, entacapone, 
fialuridine, metformin, perhexiline, pioglitazone, tolcapone, 
troglitazone, and ximelagatran (MIP DILI consortium), 
bendazac (kind gift from Dr. Dankers, Janssen Pharma-
ceuticals), adefovir (Shanghai PI chemicals), azathioprine, 
bicalutamide, buspirone, busulfan, colchicine, clotrimazole, 
danazol, furosemide, meclizine, methimazole, mexiletine, 
nitrofurantoin, nitrofurazone, primidone, procyclidine, pro-
pylthiouracil, sulindac, tacrine, thioridazine, trazodone, and 
zafirlukast (kind gift from Dr. Weida Tong, NCTR-FDA; all 
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vendors are listed in Supplemental Table 6). All compounds 
were dissolved in DMSO, except for metformin, venlafax-
ine, methapyrilene, fluphenazine, buthionine sulfoximine, 
lomustine and isoniazid (all PBS), acetaminophen, and phe-
nobarbital (DMEM). Anti-human albumin (A80-229F, poly-
colonal), was obtained from Bethyl Laboratories Inc (Texas, 
USA), anti-β-Catenin antibody (610153, monoclonal) was 
obtained from BD Transduction Laboratories (Breda, The 
Netherlands), and anti-MRP2 (M2III-6) (AB3373, mono-
clonal) was obtained from Abcam (Cambridge, UK). Goat 
anti-mouse Alexa-488 (A11001) and goat anti-rabbit Alexa-
488 (A11008) were obtained from Molecular Probes (Breda, 
The Netherlands). Hoechst 33342 (Thermo Scientific, Lei-
den, The Netherlands) 200 ng/ml was used to stain nuclei of 
live cells. Hoechst 33258 (Sigma, Zwijndrecht, The Nether-
lands); 2 µg/ml was used to stain nuclei of fixed spheroids. 
Rhodamine phalloidin was obtained from Sigma (Zwijn-
drecht, The Netherlands).
Cell lines
Human hepatoma cell line HepG2 was obtained from the 
American-type Tissue Culture Collection (ATCC, Wesel, 
Germany). HepG2 GFP BAC reporters for human SRXN1, 
NQO1, CDKN1A (p21), BTG2, DDIT3 (Chop), and HSPA5 
(BiP) have been generated previously (Wink et al. 2016). For 
experiments, HepG2 wt and GFP-BAC cell lines were cul-
tured in phenol red-free Dubelco’s modified Eagles medium 
(DMEM) supplemented with 10% (v/v) fetal bovine serum 
(FBS), 25 U/ml penicillin, and 25 µg streptomycin (PSA, 
Invitrogen).
3D cell culturing
Matrigel (cat. No: 354230) was obtained from BD Bio-
sciences (Erembedegem, Belgium). Matrigel batches vary 
in total protein concentration; a stock of matrigel was diluted 
to 5 mg protein/ml and used to culture the spheroids as 
described (Ramaiahgari et al. 2014). Cells were incubated 
at 37 °C with 5%  CO2. Culture medium was refreshed every 
3–4 days. Greiner Bio-one (Alphen aan de Rijn, The Neth-
erlands) µclear 384 well plates were used for culturing and 
confocal imaging of the spheroids.
Determination of metabolic activity of CYP450 
enzymes
A cocktail of five different chemicals (25 µM diclofenac 
(CYP2C9), 10 µM midazolam (CYP3A4), 100 µM phen-
acetin (CYP1A2), 500 µM bupropion (CYP2B6), and 15 µM 
dextromethorphan (CYP2D6)) in methanol was applied 
to 2D and 3D cultures. Cell culture supernatant was col-
lected at 0, 4, 24, and 48 h after exposure. LC–MS analy-
sis of metabolites was performed by Janssen Pharmaceu-
tics (Beerse, Belgium) in a similar way to what has been 
described earlier (Tanaka et al. 2014).
Cell treatment and viability
Compound exposures were performed in three different 
ways: 48-h single exposure, 6 days repeated, and 11 days 
repeated exposure. For 6 or 11 days repeated exposure, every 
24 h, the medium was aspirated from the cells and freshly 
diluted compound in fresh medium was added. 24 h after 
the last exposure, the imaging was started. For 48 h single 
exposure and 6 days repeated exposure, the imaging was 
started at day 28 after seeding the cells in 384 wells. For 11 
day repeated exposure, the imaging started at 33 days after 
seeding. Cell viability was measured in HepG2 wild-type 
cultures, using the ATP-lite luminescence assay kit (Perkin 
Elmer) as described previously (Ramaiahgari et al. 2014). 
Cell death was calculated as a percentage of viable cells 
after compound exposure compared to its vehicle control, 
assuming that all wells have an equal amount of spheroids. 
All experiments were performed in triplicate independent 
experiments.
Confocal microscopy image acquisition
The GFP intensity levels of reporter cell lines were deter-
mined using a Nikon TiE2000 confocal laser microscope 
equipped with an automated stage, perfect focus system 
and live cell control to ensure 37 °C and  CO2 conditions 
during imaging. Images were acquired with 20X objec-
tive (NA = 0.75, Violet Corrected) and 2X zoom. Lasers 
405 detecting Hoechst 33342 and 488 detecting GFP were 
used. An in-house build NisElements-based macro enabled 
automated image acquisition of spheroids (Supplemental 
Fig. 2). First, the macro acquired multiple images, which 
were stitched together to form a large image almost cover-
ing the entire well; software identified the spheroids in the 
large image based on Hoechst 33342 intensity. Next, the 
microscope zoomed in on individual identified spheroids 
and generating z-stacks with step size of 15 µm; this allowed 
the identification of the z-stack with maximal intensity of 
Hoechst 33342. As a last step the software acquired one 
image containing Hoechst 33342 and GFP intensity values. 
A maximum of seven spheroids were imaged per well per 
replicate treatment.
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Gene expression analysis
Open TG-GATES database “Toxicogenomics Project and 
Toxicogenomics Informatics Project under CC Attribution-
Share Alike 2.1 Japan” was used to extract primary human 
hepatocyte gene expression data as reported previously 
(Wink et al. 2016). Raw CEL files can be downloaded at: 
http://dbarc hive.biosc ience dbc.jp/en/open-tggat es/desc.html.
RNA isolation and microarray analysis of 2D and 3D 
HepG2 cells: RNA was extracted from 3-day cultured 2D 
HepG2 cells and 3D HepG2 cells cultured for 3, 7, 14, 21, 
and 28 days. Total RNA was extracted from 2D/3D cultured 
cells using Trizol reagent (Invitrogen, Carlsbad, USA) fol-
lowed by clean up using RNeasy mini kit (Qiagen, Hilden, 
Germany). RNA quality and integrity were determined using 
the Agilent bioanalyzer (Agilent Technologies Inc, Santa 
Clara, USA). Biotinylated cRNA was prepared using the 
Affymetrix 3′ IVT-Express Labeling Kit (Affymetrix, Santa 
Clara, USA) and hybridization steps were performed by Ser-
vice XS B.V (Leiden, The Netherlands) on Affymetrix HT 
Human Genome U133 plus PM plate. Array plates were 
scanned using the Affymetrix GeneTitan scanner. Raw cel 
files are submitted to GEO (Number: GSE128763). BRB 
Array Tools software (developed by Dr. Richard Simon and 
BRB-ArrayTools Development Team) was used to normal-
ize the cel files data using Robust Multichip Average (RMA) 
method. Differentially expressed genes between the various 
experimental conditions were identified with an ANOVA test 
followed by calculation of the false discovery rate accord-
ing to Benjamini and Hochberg on Partek Genomics Suite 
7.0 (Partek, Missouri, USA). Principal component analyses 
(PCA) of basal 2D/3D HepG2 gene expression were per-
formed on Partek Genomics Suite 7.0 (Partek, Missouri, 
USA). Classification of the selected genes according to 
their biological and toxicological functions was performed 
using the Ingenuity Pathway Analysis  IPA® software (Inge-
nuity Systems, Redwood, USA). Heatmap representations 
and hierarchical clustering (using Pearson correlation) were 
performed using the Multi Experiment Viewer software.
Re‑annotation, normalization, and data filtering 
for comparative gene expression profiling 
across various in vitro and in vivo models
To compare basal gene expression data from 2D and 3D 
HepG2 cells with other liver tissue/cell models, differ-
ent data sources were combined. Raw data files from 
untreated HepaRG and HepG2 cells were obtained from 
the department of Toxicogenomics, Maastricht Uni-
versity, and GEO database (3D HepG2—GSE128763; 
HepaRG—GSE109511; 2D HepG2—GSE109513). Pri-
mary cryopreserved human hepatocyte data were down-
loaded from TG-GATEs and GEO (PHH1—GSE53399; 
PHH2—GSE122660); Postmortem liver data were from 
GEO (GSE13471,GSE3526, and GSE107037). Raw data 
files were loaded into R version 2.15.2 for Windows (64-
bit), re-annotated to EntrezGene using Brainarray’s custom 
CDF version 15.1.0. The R-packages used were obtained 
from BioConductor version 2.11. Since the combined data 
set was originating from the Affymetrix Human Genome 
U133 Plus 2.0 and Affymetrix HT Human Genome U133 
plus PM (GeneTitan) platforms, normalization was per-
formed in a multi-step procedure. Data from different chip 
types were merged based on overlapping probe identifiers, 
followed by scaling of the data and quantile normalization 
on the merged set (Quackenbush 2002). Principal Compo-
nent Analysis (PCA) was applied to identify data patterns 
and to highlight data similarity and differences between 
the treated and untreated cell lines at different time points. 
PCA analysis was performed on whole-genome expres-
sion and filtered gene sets of hepatocyte-specific canonical 
pathways obtained from pathway annotation of Ingenuity 
Pathway Analysis (IPA). Differentially expressed genes 
(p < 0.05; FDR < 0.05, fold change ± 1.5) of 2D/3D HepG2 
and HepaRG compared to human liver and primary human 
hepatocyte expression were calculated using Partek Genom-
ics Suite 7.0 and provided in supplemental data. PCA data 
were also visualized using Tibco Silver Spotfire (Paulo Alto, 
CA, USA).
Transcription factor analysis
To further characterize the functional status of transcrip-
tional regulatory circuits, prediction of transcription factor 
(TF) activities based on TF-target relationship was assessed. 
TF activities were estimated following the pipeline pro-
posed in the Dorothea tool version 2 (https ://saezl ab.githu 
b.io/DoRot hEA/, (Garcia-alonso et al. 2018)). Differen-
tially expressed genes calculated for each pair 2D 3 days—
3D other days (pval < 0.001, |FC| > 1.5). In case of multi-
ple probe-gene annotation, the probe with highest FC was 
included. To estimate TF rank for each treatment, we used 
the manually curated human regulon of Dorothea v2 (Gar-
cia-alonso et al. 2018). Version 2 of DoRothEA provides 
updated TF regulons derived from a broader collection of 
resources and strategies. The new TF regulons are signed (to 
account for activation/repression), when possible, and each 
TF-target interaction has been assigned a confidence score, 
ranging from A to E, being A the most confident interac-
tions. Confidence set ABC was chosen for this analysis. We 
estimated TF activities as a proxy of the expression levels 
of the targeted genes using the analytic Rank-based Enrich-
ment Analysis (aREA) method from the viper R package 2, a 
statistical test based on the average ranks of the targets. The 
approach assumes that the activity of a TF can be estimated 
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from the mRNA levels of its direct target genes. TF scores 
have been z-scored TF-wise for all the samples.
Quantitative image analysis
Image quantification was performed with CellProfiler 
2.1.1 (Broad Institute, Cambridge, USA), HDF5 (version 
2.10.1), R (version 3.2.2), and R studio (version 0.97.551) 
as reported previously (Wink et al. 2016). Based on the Hoe-
chst33342 image, CellProfiler defines two objects: a mask 
of the entire spheroid and a mask of all the single nuclei 
combined in the spheroid. The integrated GFP intensity 
values were determined with the mask of the entire sphe-
roid and normalized for spheroid size by dividing by the 
mask of single nuclei, resulting in values for normalized 
GFP intensities.
Data processing and statistics
Possible outliers were removed based on the two-tailed 
Grubb’s test in vehicle DMSO treatment per imaged plate. 
Each treatment/dose combination was subsequently nor-
malized by the DMSO vehicle control. Final values were 
obtained by removing possible outliers in obtained fold-
change values using the two-tailed Grubb’s test. Fold 
changes were considered significant as p < 0.05 in a one-
tailed Student’s t test.
Results
Transcriptome analysis of 3D spheroid HepG2 
differentiation
Previously, we reported differentiation of HepG2 cells when 
cultured as 3D spheroids with increased liver-like proper-
ties as a result (Ramaiahgari et al. 2014). Our objective in 
the current study was to assess the applicability of HepG2 
fluorescent cellular stress response reporters in 3D differen-
tiated screening systems. As a first step, we further charac-
terized the 3D differentiation in more detail using detailed 
whole-genome transcriptome analysis in comparison with 
other liver model systems. First, we evaluated the gene 
expression profile of HepG2 cultured in 2D monolayers 
with HepG2 cultured as 3D spheroids (Fig. 1a–d; Supple-
mental Fig. 1). Gene expression profiles of 2D monolayer 
at 3 days after seeding as well as 3D spheroid samples at 
3, 7, 14, 21, and 28 days after seeding were retrieved. A 
change in the gene expression of 3D cultured genes was 
observed with a strong increase at day 14 (Supplemental 
Fig. 1A). This shift in gene expression changes after day 
14 can also be observed in a principal component analy-
sis (PCA) (Fig. 1b). Genes representing differentiated liver 
functions associated with fetal hepatocyte differentiation 
were strongly up-regulated (Fig. 1c) (Takebe et al. 2013). 
To further examine these changes, regulatory transcription 
factors were extracted in the comparison between 2D and 
3D samples. Top 50 transcription factors revealed major 
changes in liver-specific transcription factors (HNF4α, C/
EBP, EGR1, and FOXA1) (Fig. 1d; Supplemental Table 2) 
(Guerquin et al. 2013; Guzman-lepe et al. 2018). For the 
top five TFs, we observed large down-regulated regulons 
for E2F4 and ETS1 (mainly involved in cell cycle) (Hsu 
and Sage 2016; Fry and Inoue 2018) with suppressed activ-
ity over time, and large up-regulated regulons for HNF4α, 
C/EBP, and STAT1 (mainly involved in differentiation) 
with increased activation over time (Fig. 1d; Supplemental 
Fig. 1B, C) with various transcripts in common for these 
differentiation TFs. These results support the improved 
liver-like properties in 28 day 3D spheroid cultured HepG2 
cells (Ramaiahgari et al. 2014). To investigate whether these 
gene expression changes also correlate with gene expression 
profile in other liver systems, we compared 2D HepG2 mon-
olayer cultures and 3D HepG2 spheroids (at 28 days) with 
primary human hepatocytes, HepaRG cells, and human liver. 
Important functional pathways of hepatocytes were selected 
and compared in the different liver models using a PCA plot 
(Fig. 1e). For all pathways selected, a shift is observed of 
3D HepG2 spheroids from 2D HepG2 towards human liver. 
This supports the differentiation of HepG2 cells towards 
more liver-like cells when cultured in a 3D matrigel environ-
ment. We further systematically compared gene expression 
profiles (fold change ± 1.5; p < 0.001) of HepG2, primary 
human hepatocytes (PHH), HepaRG, and human liver (see 
Supplemental Table 1). Of particular interest, delta-like 
1 homolog (DLK1) was > 100-fold higher in 3D HepG2 
spheroids compared to PHH and HepaRG. In particular, we 
observed increased expression of factors involved in differ-
entiation. Thus, DLK1 is associated with Notch signaling 
pathway, and was shown to have a role in development and 
differentiation of various tissue types such as liver, lung, 
adipose tissue, and skeletal muscle (Falix et al. 2012). Sex 
Determining Region Y-Box 9 (SOX9), which has a role in 
embryonic development of various tissues, was 20-fold and 
ninefold higher in 3D HepG2 compared to PHH and Hep-
aRG, respectively. Similarly, Forkhead Box Q1 (FOXQ1) is 
12- to 14-fold higher in 3D HepG2 spheroids (Bieller et al. 
2001). As a likely consequence of this enhanced differen-
tiation, the terminal hepatocyte differentiation marker Glu-
cose-6-phosphatase (G6PC) gene was 4- to 11-fold higher 
in 3D HepG2 spheroids compared to PHH and HepaRG. 
Cell cycle-related genes such as CCND2, CCND3, CDK9, 
CDKN1A, CFL1, ECT2, KIF11, MDM2, etc. were down-
regulated in 3D HepG2 spheroids compared to PHH, and this 
effect was much more pronounced in comparisons with Hep-
aRG cells, indicative of the non-proliferating differentiated 
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phenotype of HepG2 spheroids. On the contrary, relative 
gene expression levels of cytochrome P450 enzymes were 
generally higher in PHH and HepaRG cells, indicating that 
the enhanced differentiation did not lead to equal levels of 
metabolism enzymes. Analogous to previous findings (Lim-
onciel et al. 2018), basal-level expression of GAGE genes 
which are associated with cancer were significantly higher 
in HepaRG cells with an 80- to 100-fold change increase. 
Apolipoprotein C2 (APOC2), Inter-Alpha-Trypsin Inhibitor 
Heavy Chain 3 (ITIH3), Protein C Inactivator Of Coagula-
tion Factors Va And VIIIa (PROC), DnaJ Heat Shock Pro-
tein Family (Hsp40) Member C15 (DNAJC15), and Thyroid 
Hormone Responsive (THRSP) were top down-regulated 
genes in HepaRG compared to PHH (Supplemental Table 1).
Liver‑like spheroid differentiation of fluorescent 
reporter HepG2 cell lines
To verify whether the various GFP reporter cell lines could 
differentiate into 3D liver-like spheroids in a similar man-
ner as wild-type HepG2, we cultured Srxn1-GFP, Nqo1-
GFP, Chop-GFP, BiP-GFP, Btg2-GFP, and p21-GFP in 3D 
matrigel. After 28 days, all wells were stained for nuclei 
and F-actin as well as for liver-like properties that are not 
present in 2D HepG2 monocultures; e.g., bile duct formation 
(MRP2), albumin expression, and basal-lateral polarization 
(β-catenin) (Ramaiahgari et al. 2014). All BAC-GFP HepG2 
reporter cell lines analyzed acquired the similar type of dif-
ferentiation as HepG2 wild type (Fig. 2a, b).
3D HepG2 spheroids have an improved metabolizing 
capacity compared to 2D monolayers. Therefore, next, we 
evaluated the activity of some CYP450 enzymes in a subset 
of the reporter lines (Srxn1-GFP, p21-GFP, Chop-GFP, and 
BiP-GFP). For this, we measured the CYP450 metabolic 
capacity of the cells in 2D and 3D cultures using a mixture 
of five different substrates and LC–MS analysis. The com-
pound-specific CYP450 enzyme activity allowed the exact 
determination of the CYP450 enzyme activity. Enhanced 
metabolizing capacity of CYP3A4, CYP2C9, CYP2B6, 
CYP1A2, and CYP2D6 was observed in 3D cultures for 
all reporter cell lines tested, to a similar extend as wild-
type HepG2 spheroids. These combined data demonstrate a 
differentiated liver-like phenotype of all GFP reporter cell 
lines.
Confocal imaging‑based detection of GFP reporter 
activity in 3D liver spheroids
We previously determined the specific activation of GFP 
stress response reporter activation dynamics in 2D mon-
olayer reporter cultures (Wink et al. 2016). To determine the 
functionality of our reporters in 3D spheroids, we applied 
well-established reference chemicals that specifically acti-
vate the stress response pathways: tert-butylhydroquinone 
(tBHQ) for the oxidative stress response pathway (Srxn1-
GFP and Nqo1-GFP); tunicamycin for the UPR pathway 
(BiP-GFP and Chop-GFP); and aflatoxin B1 for the DNA 
damage response pathway (p21-GFP and Btg2-GFP). The 
effect of the reporter activity was evaluated using confocal 
microscopy followed by quantitative image analysis (Wink 
et al. 2016). All six reporter cell lines demonstrated strong 
and significant up-regulation of GFP intensity after stim-
ulation with reference inducers (Fig. 3a, b). This demon-
strates that all the BAC-GFP reporter cell lines remain their 
sensing properties under 3D culture conditions which can 
be detected and quantified using our confocal microscopy 
settings.
3D spheroid reporter responses represent 
drug‑induced gene activation in primary 
human hepatocytes
As a next step, we systematically compared the reporter 
responses of the 3D spheroid system to primary human 
hepatocytes gene expression data from the TG-GATEs 
database. The TG-GATEs database contains gene expres-
sion data of ~ 150 compounds exposed to primary human 
hepatocytes in three different concentrations and three differ-
ent time points (Supplemental Table 3). For each of the six 
GFP reporter genes, we ranked the TG-GATES compounds 
(at high dose, 24 h treatment) based on fold change. For each 
reporter, ten compounds were selected (except for Chop-
GFP; only nine compounds were used) originating from 
the top 12 ranked compounds that caused up-regulation of 
Fig. 1  Transcriptome profile of HepG2 cells cultured as 3D sphe-
roids. a Phase contrast images of HepG2 cells in 3D Matrigel cultures 
over a period of 28 days. Scale bars 100 μm. b Principal Component 
Analysis plot of basal-level whole-genome gene expression of 2D 
HepG2 cells at day 3 and HepG2 spheroids at various timepoints in 
3D culture. c Fold change expression of genes involved in differen-
tiation and development of the liver (see gene list Takebe et  al.) in 
HepG2 spheroids at various time periods in 3D culture compared 
to 2D monolayer cultures, data are average (four experiments) fold 
change compared to 2D HepG2 gene expression. d Transcription fac-
tor (TF) rank plot: TF (y-axis) are ranked for the number of the asso-
ciated differentially regulated target genes (x-axis) in the different 2D 
vs 3D time point comparisons. Colors represent the different 2D vs 
3D time point comparisons. TFs are ranked for the comparison 2D 
vs 2D-day28 (violet). Only top 50 TFs are shown. d Top right panel. 
Activity of top 5 TFs plot: TF activity (y-axis) is shown for the 5 TF 
that have largest regulon differentially expressed (colors) for the dif-
ferent 2D vs 3D time points comparisons (x-axis). TF scores have 
been z-scored TF-wise for all the comparisons. e Principal component 
analysis of pathways related to hepatocyte function and differentia-
tion: cell cycle regulation, xenobiotic metabolism, bile acid biosyn-
thesis, complement system, liver proliferation, and liver metabolism, 
in 2D/3D HepG2 cells, primary human hepatocytes, HepaRG cells, 
and human liver (color figure online)
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mRNA levels of the respective genes in PHH. Since a major 
advantage of 3D HepG2 spheroid cultures is the ability to 
perform repeated treatments (Ramaiahgari et al. 2014), we 
also assessed which exposure regimen did correspond best 
with the PHH TG-GATEs transcript data: 48 h single expo-
sure, 6 day repeated exposure, or 11 day repeated exposure 
treatment conditions. For direct comparison, we used the 
same three concentrations used in TG-GATEs (Supplemen-
tal Table 4). To apply the 3D GFP reporter system for phar-
maceutical screening automated imaging, we established 
an automated imaging strategy (see Supplemental Fig. 2). 
All 3D GFP reporter lines show significant increases in 
Fig. 2  Characterization of the differentiated phenotype of 3D liver-
like spheroid HepG2 GFP reporter cell lines. a Wild-type (upper 
panel) and Srxn1-GFP (lower panel) spheroids are stained with 
nuclear staining  Hoechst33258 (blue), F-actin staining rhodamine 
phalloidin (red). Immunofluorescent labeling with MRP2 (upper 
row), β-catenin (middle row), and albumin (lower row) are shown in 
green. Merged images contain all three stainings (Hoechst, F-actin, 
and GFP labeling). ‘No staining’ shows basal GFP background sig-
nal. White scale bar indicates 100 µm scale. b GFP labeling of wild-
type HepG2, Srxn1, p21, Chop, and BiP reporter lines are shown for 
MRP2 (upper row) and albumin expression (lower row). White bar 
indicates 100  µm scale. c Five different metabolites were measured 
in 2D monolayers and 3D spheroids for 48 h. 1-OH-midazolam was 
measured as a measurement for CYP3A4 function, dextrorphan as 
a measurement for CYP2D6 function, phenacetin as a measurement 
of CYP1A2 function, OH-bupropion as a measurement for CYP2B6 
function, and 4-OH-diclofenac as a measurement for CYP2C9 func-
tion. Graphs show averages of three technical replicates and is nor-
malized to the average amount of cells as represented by the average 
ATP content of 80 parallel 384-well 2D and 3D cultures (color figure 
online)
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the TG-GATES (Fig.  4; Supplemental Fig. 3). In addi-
tion, all reference control compounds were positive in their 
corresponding reporters; for some maximal response was 
observed after 48 h (aflatoxin B1: Btg2-GFP and p21-GFP 
reporters); for others, this was primarily at 6 day repeated 
exposure (tBHQ: Srxn1-GFP and Nqo1-GFP; and thapsi-
gargin: BiP-GFP). Chop-GFP responses were low, but in the 
range of what was expected based on 2D reporter activity 
(Supplemental Fig. 3) (Wink et al. 2016). For the selected 
TG-GATEs compounds, most significant reporter activa-
tion was observed for the 6 and 11 day repeated exposure 
compared to 48 h single exposure. In particular, the Srxn1-
GFP and BiP-GFP reporters were most representative for the 
TG-GATEs’ PHH transcriptomics responses (Supplemen-
tal Fig. 3). For all six reporter lines, the average combined 
sensitivity was 86%, with Srxn1-GFP as a single reporter 
even a 100% sensitivity (Supplemental Table 4). Thus, the 
3D repeated exposure reporter activity showed high resem-
blance with gene expression data of primary human hepato-
cytes. This notion was further supported when comparing 
the fold changes of the TG-GATEs data set with the maxi-
mal fold change obtained from our 3D reporter system (Sup-
plemental Table 5). Taken together, we conclude that our 
3D BAC-GFP stress response reporter system shows high 
resemblance with responses observed in PHH.
Drugs with clinical DILI concern activate stress 
response reporters in 3D spheroids
To further study the applicability of the 3D BAC-GFP 
reporter cell lines in drug safety assessment screening, a 
systemic analysis of in total 33 drugs was performed with 
known DILI liabilities: 20 drugs categorized as most-DILI-
concern drugs, 7 drugs with less-DILI concern, and 6 drugs 
with no-DILI-concern drugs were selected (Supplemental 
Table 6). These compounds were selected based on lim-
ited sensitivity in our 2D HepG2 reporter study (Wink 
et al. 2018). The evaluation was conducted with six GFP 
reporter cell lines: Srxn1-GFP, Nqo1-GFP, p21-GFP, Btg2-
GFP, BIP-GFP, and Chop-GFP. 3D spheroids were treated 
for 48 h single exposure or 6 day repeated exposure using 
concentrations that were based on peak plasma levels meas-
ured after administrations to patients during clinical trials 
(Cmax): 1, 5, 10, 25, 50, and 100 times Cmax (Dawson et al. 
2012; Khetani et al. 2013; Jenkins et al. 2009; Keisu and 
Fig. 3  Application of 3D spheroid HepG2 GFP reporters in auto-
mated confocal microscopy. Representative images of single 3D 
spheroids for Srxn1-GFP and Nqo1-GFP (150  µM t-BHQ); BiP-
GFP and Chop-GFP (12 µM tunicamycin); p21-GFP (5 µM aflatoxin 
B1) and Btg2-GFP (25 µM aflatoxin B1) compared to 0.1% DMSO 
control. The graphs show response of individual spheroids as a fold 
change over average DMSO intensity; colors represent different bio-
logical replicates (color figure online)
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Andersson 2010; Regenthal et al. 1999; O’Brien et al. 2006; 
Xu et al. 2008; Gustafsson et al. 2014). Six positive refer-
ence control compounds, DEM, tunicamycin, and aflotox-
inB1 were included on all imaging plates (Supplemental 
Table 7).
To verify compound potency for onset of cytotoxicity, 
we first compared the effect on viability between single and 
repeated exposure in parental HepG2 3D spheroids (Sup-
plemental Fig. 5). Several DILI compounds caused cyto-
toxicity after 48 h at the highest concentrations, which was 
further increased with 6 day repeated exposure, in particu-
lar for compounds with severe-DILI liabilities; cell viability 
remained constant for compounds with no-DILI concern.
Next, we systematically determined the GFP reporter 
activation in individual spheroids for all DILI compounds 
in the six reporter cell lines. An increase of GFP reporter 
activity was observed for various DILI compounds, also 
those for which responses in 2D HepG2 have so far not been 
observed (Wink et al. 2018). Some variability in responses 
between spheroids was evident for different reporters, indi-
cating the importance to include multiple spheroids in the 
analysis (Fig. 5). In general, stress response activation was 
strongest affected by DILI compounds after 6 day repeated 
exposure (Supplemental Fig. 4). The positive control group 
showed significant concentration-dependent up-regulation 
of the selective pathway reporters. Concentration-dependent 
responses were observed for most-DILI compounds; how-
ever, some compounds (e.g., trovafloxacin, tolcapone, and 
clozapine) displayed a decrease in activity at the highest 
concentrations, especially in 6 day repeated exposure. This 
correlates with a strong increase in overall cytotoxicity (see 
Supplemental Fig. 5 and Supplemental Table 6). BiP-GFP 
was most sensitive at 6 day repeated exposure, followed by 
Srxn1-GFP; no direct overlap in responses was observed 
between BiP-GFP and Srxn1-GFP activation. BiP-GFP 
and Srxn1-GFP were most sensitive for the majority of 
most-DILI-concern compounds; Nqo1-GFP was not sig-
nificantly up-regulated by any of the compounds, likely due 
to high basal levels of the Nqo1-GFP under control condi-
tions. Interestingly, trovafloxacin induced all three different 
pathways; remarkably, the less-DILI-concern compound 
adefovir did activate the BiP-GFP, Btg2-GFP, and p21-GFP 
reporters. We performed hierarchical clustering of the 6 
day repeat exposure data to compare compound responses 
(Fig. 6). Six clusters were distinguished (clusters I–VI): five 
clusters (clusters I–V) with activation of multiple pathways 
and one cluster (cluster VI) with minor activation in one 
pathway (mainly BiP-GFP). Three clusters are formed by 
one compound (trovafloxacin, adefovir, and bicalutamide), 
for their distinct activation of BiP-GFP (trovafloxacin and 
bicalutamide) and p21-GFP (adefovir). Clusters III and 
V are characterized by an activation of mainly BiP-GFP 
and Srxn1-GFP in the higher concentrations. 5 out of 7 
Fig. 4  Example of cellular stress response GFP reporter activation by reference 
DILI compounds in 3D spheroids. Srxn1-GFP, Nqo1-GFP, BiP-GFP, Chop-
GFP, p21-GFP, and Btg2-GFP were exposed to ten different compounds from 
top 12 inducers in the TG-GATES primary human hepatocyte data set. For 
each reporter, one example compound is shown for 48 h single exposure (blue), 
6 day repeated exposure (green), and 11 day repeated exposure (red). Graphs 
are the fold-change of average DMSO response and are displayed as mean val-
ues with 95% confidence interval over all spheroids tested as error bars. Con-
centrations are the same as tested in the TG-GATES data set (see Supplemen-
tal Table 5) (color figure online)
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Fig. 5  Concentration response 
activation of 3D spheroid GFP 
reporter stress response pathway 
by most-DILI-concern drugs. 
One most-DILI-concern drug 
for each Srxn1-GFP, Nqo1-
GFP, BiP-GFP, Chop-GFP, p21-
GFP, and Btg2-GFP is shown in 
concentration response graphs 
for 48 h single exposure and 
6 day repeated exposure. The 
graph shows mean fold change 
with 95% confidence interval 
error bars. Significance is tested 
with a one-tailed student’s t test 
with *p < 0.05 and **p < 0.01. 
Two example images are 
shown for DMSO control and 
six example images are shown 
for one concentration of a sig-
nificantly induced most-DILI-
concern drug
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less-DILI-concern compounds are in activated clusters I–V. 
Cluster VI also contained DMSO control as well as 5 out of 
6 no-DILI-concern compounds; also 6 out of 20 most-DILI-
concern compounds. Thus, hierarchical clustering resulted 
in an overrepresentation of most-DILI-concern compounds 
in activated clusters, suggesting 70% sensitivity and 83% 
specificity.
Finally, we compared the response in our 3D HepG2 
GFP reporter DILI screen with our recently reported 2D 
HepG2 GFP reporter DILI screen data (Wink et al. 2018). 
Benchmark concentrations (BMC) were calculated, defined 
as the concentration where the GFP fold change exceeded 
the 1.5 threshold (Ritz et al. 2015). Nqo1-GFP was left out 
of this analysis due to a lack of activation. For only one 
Fig. 6  Hierarchical clustering of reporter activation of different 
reporters by compounds with different DILI-concern. Heatmap was 
based on GFP fold-change responses depicted in Supplemental Fig. 4; 
red intensity is indicative for higher FC response. Ward.d hierarchi-
cal clustering was performed with all GFP responses of all 6 day 
repeated exposure tested. Left color bar indicates type of compound: 
purple for negative control DMSO, light blue for no-DILI-concern 
drugs, red for less-DILI-concern drugs, and green for most-DILI-con-
cern drugs. The six reporters are depicted in alphabetical order, with 
concentration responses from 1, 5, 10, 25, 50, and 100 Cmax (from left 
to right). Arrows indicate the branch where the cluster diverges from 
the main tree (color figure online)
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no-DILI-concern compound, BMC values could be deter-
mined for Srxn1-GFP and Btg2-GFP. Compounds with a 
relatively low BMC in relation to the human plasma Cmax 
value were typically most-DILI-concern compounds (tro-
vafloxacin, clozapine, perhexiline, and bicalutamide). In 
addition, the dotted regression line shows a lowering trend 
in BiP-GFP, Btg2-GFP, and Srxn1-GFP for most-DILI-con-
cern drugs compared to less- and no-DILI-concern drugs. 
For four drugs that were not detected in 2D monolayer, 
bicalutamide, mexiletine, trazodone, and zafirlukast, the 
concentration response curves for Srxn1-GFP, Chop-GFP, 
and p21-GFP reporters were compared between our current 
3D spheroid screen and our previous 2D live reporter screen 
(Wink et al. 2018). In 2D, only few drugs exceeded the 25% 
GFP positive cell threshold; in 3D spheroids, almost all four 
compounds reached the 1.5-fold change threshold (Fig. 7b). 
We also compared the 2D and 3D BMC values for the 
Srxn1-GFP, Chop-GFP, and p21-GFP reporters, and defined 
the compounds for which a BMC could be derived in either 
2D and/or 3D in any of the three reporters (Supplemental 
Fig. 7  Comparison of 2D monolayer and 3D spheroid GPF reporter 
responses by DILI compounds. a 3D 6 day repeated treatment BMC 
values (y-axis) depicted with corresponding Cmax values (x-axis). 
Dotted lines indicate regression separated for the different DILI-con-
cern classes. Most-DILI-concern in green, less-DILI-concern in red, 
and no-DILI-concern in blue. b 2D versus 3D dose-range comparison 
for bicalutamide, mexiletine, trazodone, and zafirlukast. The black 
line represents the 3D concentration curve; the red line depicts the 2D 
response as percentage GFP positive cells as most sensitive marker 
(Wink et al. 2016). The dotted line is the BMC threshold in 2D and 
3D. c 2D (x-axis) plotted against the 3D BMC (y-axis) for the over-
lapping compounds in the different cell lines. The compounds were 
color coded for distribution for the cell lines (left) and the DILI-con-
cern (right). d Histogram of accumulative number of compounds with 
available BMC determined in 2D only, 3D only, or overlap-2D&3D. 
The compounds were colored for DILI-concern (left), metabolism 
information (middle), and the treatments (right) (color figure online)
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Table 8). This resulted in a group of compounds for which 
a BMC was derived in “2D only”, “3D only”, or “overlap 
2D&3D”. For the “overlap 2D&3D” group, typically, a 
lower BMC was derived in the 3D spheroid condition, which 
was particular in the Srxn1-GFP reporter and largely reflect-
ing severe-DILI-concern compounds (Fig. 7c). No overlap 
was observed between 2D and 3D for the p21-GFP reporter; 
only one less-DILI-concern drug showed an overlap in 2D 
and 3D and none of no-DILI-concern was detected under 
both conditions. Finally, we compared the overall positive 
calls for both 2D and 3D reporter screen results based on 
BMC levels; for this, we addressed three different labeling 
conditions: FDA DILI-concern label, involvement of drug 
metabolism, and DILI compound (Fig. 7d). The majority of 
BMCs were derived under 3D spheroid reporters conditions, 
and reflected in particular less-DILI-concern compounds, 
that involve liver drug metabolism.
Discussion
Here, we have systematically evaluated the application of 
HepG2 BAC-GFP cellular stress response reporters as 3D 
differentiated liver-like spheroid systems for the assessment 
of DILI liability. Our results indicate that various cellular 
stress response reporters have a differentiated phenotype 
in 3D matrigel culture, show enhanced metabolic capac-
ity, and are amenable for confocal imaging-based reporter 
activation assessment in a high-throughput manner. The 
systematic analysis of the reporter activation of a subset of 
DILI compounds indicates that improved identification of 
DILI liability in 3D spheroids, compared to 2D monolayer. 
The BiP-GFP and Srxn1-GFP reporter cell lines seem most 
promising for implementation in 3D spheroid-based DILI 
assessment.
To our knowledge, this is the first fluorescent protein-
based reporter system to follow and quantify the activation 
of endogenous stress response protein expression in sphe-
roid systems. While primary human hepatocyte spheroids 
have been applied for DILI assessment (Proctor et al. 2017), 
the biomarkers available to cost-effectively quantify endog-
enous biomarkers for mode-of-action at a single spheroid 
level in a high-throughput setting have not been possible 
so far. We combined our GFP reporter platform and the 
enhanced liver-like properties of HepG2 3D spheroid cul-
tures. We reported that our 3D HepG2 spheroid model has 
enhanced differentiated liver-like properties which is related 
to increase in transcriptional activity of HNF4α, CEBP, and 
STAT1, which are involved in liver differentiation, in asso-
ciation with decreased activity of E2F4 and EST1, that are 
involved in liver cell proliferation. HNF4α promotes hepato-
cyte cell polarity and differentiation (Parviz et al. 2003), 
and drives the activation of promoter regions of G6PC and 
PCK1. The two latter genes are considered key markers of 
differentiated hepatocytes (Hall et al. 1995; Boustead et al. 
2003; Parviz et al. 2003). Of relevance, we found that G6PC 
and PCK1 were top two up-regulated genes at day 28 in 
3D HepG2 spheroids with ~ 235- and 132-fold increase in 
gene expression compared to 2D HepG2 cultures. C/EBPα 
also plays a major role in differentiation and ‘hepatogen-
esis’ (Yuan et al. 2015). STAT1 was shown to negatively 
regulate cell proliferation of hepatocellular carcinoma and in 
differentiation of metanephric mesenchymal progenitor cells 
during kidney development (Wang et al. 2010; Chen et al. 
2013). These data support the more liver-like phenotype 
of the 3D HepG2 system. While the 3D HepG2 spheroids 
showed close association with other more differentiated 
liver test systems, our data indicate that the cells reflect a 
fetal hepatocyte status. We demonstrated that GFP HepG2 
reporter cell lines also differentiate in a comparable manner 
as the HepG2 wild-type cells, as evidenced by various dif-
ferentiation markers including formation of MRP2-positive 
bile canaliculi-like structures, albumin protein expression, 
and enhanced phase 2 metabolizing enzyme activity. We 
established a high-throughput confocal microscopy method 
to automatically acquire and analyze GFP reporter activity 
in 3D spheroids. Well-established positive reference com-
pounds showed robust up-regulation of GFP intensity of 
all six reporter lines validating the image acquisition and 
quantification method. Moreover, based on TG-GATES 
selected compound screening, we were able to verify that 
our 3D system shows very high concordance with primary 
human hepatocyte responses, as sensitivity ranges from 70 
to 100%. By establishing this concordance, we make note 
of the downsides of the TG-GATES data set, since this data 
set contains only two replicates and different TG GATES 
compounds with unusual concentration responses. Grinberg 
et al. (2014) listed SV3 genes which do show convincing 
results. Four of the six genes that were compared with our 
HepG2 data were part of this list. Therefore, we conclude a 
high concordance with primary human hepatocytes.
Our current 3D spheroid reporter platform seems to 
outperform the same reporter cells when used in a 2D 
monolayer configuration in the context of identification 
of DILI liabilities. In our current 3D screen, we purposely 
included severe-DILI-concern compounds that were pre-
viously observed as negative in our 2D reporter setting 
(Wink et al. 2018), including bicalutamide, trazodone, and 
zafirlukast. These compounds caused a significant concen-
tration-dependent activation of different reporters in the 3D 
spheroid configuration. Comparison of BMCs between 3D 
spheroids and 2D monolayer configurations further sup-
ported the superiority of the 3D setting. Of relevance, drugs 
that are metabolized in the liver did represent a large portion 
of the compounds where BMC definition was only possible 
in 3D spheroid reporter. This suggests a role for the more 
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differentiated phenotype, included drug metabolizing capac-
ity, of the 3D spheroids, although we cannot exclude that 
the repeated dosing treatment regimen also contributes to 
this difference. Yet, repeated dosing in 2D monolayer is dif-
ficult due to the relatively high proliferation rate of HepG2 
cells. Given the fact that 3D HepG2 spheroid cultures are 
differentiated and lack proliferating cells, we anticipate that 
the 3D spheroids reflect a more physiological situation with 
respect to stress response activation. As such, we would 
propose a tiered testing approach where the reporters in 2D 
monolayer reflect a rapid and cost-effective tier 1 testing 
setting allowing dynamic imaging of stress reporter activa-
tion (Wink et al. 2018) and the 3D spheroid would mimic a 
more physiological relevant conditions, but are more time 
consuming and costly.
Several of the selected most-DILI-concern compounds 
were inactive in our GFP reporter system, including busul-
fan, flucloxacillin, ximelagatran, fialuridine, isoniazid, and 
methimazole. Four of the inactive most-DILI-concern drugs, 
flucloxacillin, ximelagatran, methimazole, and isoniazid, are 
associated with immune-related liver injury (Kindmark et al. 
2008; Daly et al. 2009; Cheung et al. 2015; Heidari et al. 
2015; Metushi et al. 2016). We anticipate that there are clear 
rationales why we would fail to identify these most-DILI-
concerns compound in our current reporters. Flucloxacillin, 
ximelagatran and methimazole are more specifically linked 
to single-nucleotide polymorphisms in the human leuko-
cyte antigen (HLA) allele, typically associated with iDILI 
responses. Genome-wide association study (GWAS) has 
identified HLA-B*5701 single-nucleotide polymorphisms 
involved in flucloxacillin-mediated liver injury(Daly et al. 
2009). Similarly, for ximelagatran, a strong association was 
found between elevated ALAT levels and single-nucleotide 
polymorphisms in DRB1*07 and DQA1*02 (Kindmark 
et al. 2008). Also, for methimazole, an increased risk was 
observed for HLA-B*38:02:01 carriers and onset of agranu-
locytosis (Cheung et al. 2015). Also for isoniazid, involve-
ment of immune-mediated mechanisms of liver injury may 
be of importance (Metushi et al. 2016). The mechanism of 
fialuridine induced liver injury has been suggested to be 
mitochondrial related (Mckenzie et al. 1995) due to inhibi-
tion of the mitochondrial DNA replication; typically, this 
response takes several weeks, and might be missed in the 
6 day repeat exposure, which may not have culminated in 
the activation of cellular stress responses. For future stud-
ies, we might require integration of immune-related and 
mitochondrial related toxicity in our reporter platform. This 
could be simply mitochondrial mass detection using GFP-
BAC constructs for mitochondrial markers. For immune-
mediated signaling, this could involve signaling component 
downstream of cytokine signaling (Fredriksson et al. 2011), 
although more complex adaptive immune response signaling 
would not allow integration in reporter systems.
Isoproterenol is the only no-DILI-concern compound 
which is clustered in an activated cluster. Isoproterenol is 
a β-adrenal-receptor agonist which has been labeled with 
no-DILI-concern. In rats, isoproterenol induces TNF-α and 
IL-6 elevation indicating induction of an innate immune 
response (Deng et al. 2015). Possibly, this is related to mild 
stress responses which are observed in our reporter assay; 
but this would require more detailed investigations.
The less-DILI-concern drugs represent a group of drugs 
which induces different classes of mild liver injury. To ana-
lyze these mild liver injuries, these classes of DILI are added 
as were previously established (Supplemental Table  6) 
(Wink et al. 2018). Two less-DILI-concern drugs (clotri-
mazole and metformin) are part of cluster VI, which did not 
show elevation of stress responses in are screen. It should be 
noted that both drugs show only very mild clinical indica-
tions of DILI. Interestingly, less-DILI-concern drugs with 
hepatotoxicity ranking “cholestasis steatohepatitis” (ade-
fovir and chlorpromazine) have increased stress responses 
in our assay, suggesting that these genes are up-regulated 
upon cholestasis or steatosis. In addition, elevations of stress 
responses by individual compounds can be evaluated in more 
detail in favor of mechanistic insight. These observations can 
be anchored in already existing adverse outcome pathways 
(AOPs) to elucidate the complexity of DILI toxicity. For 
the AOP that describes bile salt export pump inhibition was 
developed (Vinken et al. 2013), bosentan and troglitazone 
used in our study are listed. Oxidative stress was marked as 
one of the key event parts of the AOP. We found increased 
levels of Srxn1-GFP caused by both compounds, indicative 
for oxidative stress induction.
The enhanced liver-like properties present in 3D sphe-
roids compared to 2D monolayer culturing not only pro-
vides the advantage of enhanced metabolizing capacity but 
also enables repeated dose exposures. After approximately 
7–14 days, 3D spheroids stop proliferating and start differ-
entiating (Ramaiahgari et al. 2014). This means that from 
this moment, the spheroids will not overgrow and can be 
maintained for several weeks afterwards. This allows the 
possibility of repeated dose exposure. In many cases of idi-
osyncratic DILI, latency time varies from the first week to 
2 years after administration. During this period, patients 
obtain at least a daily dose of the drug. By applying fresh 
drug every day for 6 or 11 days, we resemble closer the 
human drug administration situation, which seems pivotal to 
hepatotoxicity screening. This is recognized by much higher 
sensitivity values in both 6 and 11 day repeated exposure 
compared to 48 h single exposure (Supplemental Table 4). 
Currently, we lack the information on the intracellular con-
centrations and drug accumulation in our 3D spheroid sys-
tem. The current concentration ranges were based on human 
peak plasma levels (Cmax). For in vitro repeated dose stud-
ies, it has been shown that drugs can accumulate to high 
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intracellular concentrations (Wilmes et al. 2013). For the 
same drug, postmortem studies showed 53-fold increase 
compared to Cmax levels (Lensmeyer et al. 1991). Both stud-
ies indicate intracellular accumulation of drugs in vitro and 
in human tissue. Therefore, we are convinced that repeated 
dose exposure in a broader concentration range that extends 
above the (predicted) Cmax concentration is essential in DILI 
liability assessment.
The current study provides suboptimal sensitivity and 
specificity levels to accurately discriminate most-DILI-
concern from no-DILI-concern drugs. We see several solu-
tions to improve this. First, we need to extend the number 
of stress response endpoints and likely include immune and 
mitochondrial pathways to increase predictivity. Second, we 
will integrate bioinformatics approaches to identify a classi-
fier that will rank drugs for DILI liability based on pathway 
activation, as well as on multiple defined criteria, including 
combinations of activated stress pathways, BMC, viability, 
and TC50 values. Such a classifier will likely increase the 
sensitivity and specificity determinants.
The application of 3D spheroids for primary human 
hepatocytes has recently been systematically evaluated 
both assessment of adverse drug response and DILI liabil-
ity (Bell et al. 2016; Proctor et al. 2017) as well as more 
recently to replicate disease states (Hendriks et al. 2016). 
These models show a strong physiological relevance with 
respect to gene and protein expression compared to human 
liver (Bell et al. 2018). These models currently rely on (com-
mercial) (pooled) cryopreserved primary human hepatocyte 
sources with limited batch volume, thus continues requiring 
batch-to-batch validation and quality control. Moreover, the 
assessment of mechanistic mode-of-action biomarkers has 
yet not been integrated and validated in these physiological 
systems. Our 3D HepG2 fluorescent reporter platform may, 
therefore, be a robust, cheaper, and sustainable alternative 
solution and contributor to provide mechanistic information 
for DILI liability assessment.
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